Rare genetic variants known to cause cardiomyopathy (an inherited cause of a weak heart) can increase the risk of patients developing heart failure. However, new research from Mass General Brigham Heart and Vascular Institute and the Broad Institute of MIT and Harvard reveals that dapagliflozin (a medication used to treat type 2 diabetes), is particularly effective at reducing the risk in individuals who are genetically predisposed to developing heart failure.
